Global Dependent Insulinotropic Receptor Market is segmented, By Product Type (DA-1241, GSK-2041706, HD-0471042, HD-0471953, HOB-047, MBX-2982, Others), By Application (Type 2 Diabetes, Obesity, Chronic Obstructive Pulmonary Disease (COPD), Dyslipidemia, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Market Overview
The "Global Dependent Insulinotropic Receptor Market" is estimated to reach at a high CAGR during the forecast period (2023-2030)
The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the GIPR gene. GIP-R is a member of the 7-transmembrane protein family, a class of G protein.
Market Dynamics
The global dependent insulinotropic receptor market growth is driven by the increasing incidence of diabetes, obesity, sedentary lifestyles, growing geriatric population, and unhealthy dietary habits. A more significant number of individuals are suffering from chronic lifestyle diseases.
The increasing incidence of diabetes population globally is expected to drive the global dependent insulinotropic receptor market growth.
Diabetes is a chronic, life-threatening disease with an unknown cure. It has been emerged as a global epidemic and affected millions globally. Furthermore, Type 1 diabetes is caused due to an immune system malfunction. Hence, Type 1 diabetes can be characterized most by insulin-requiring. The number of people who have diabetes in regions such as MEA and APAC is increasing, which in turn is propelling the demand for the dependent insulinotropic receptor market. For instance, as per the International Diabetes Federation 2017, more than 72,946,400 new cases of diabetes were diagnosed in India.
At present, China has the highest number of diabetes patients globally. In addition, the prevalence of diabetes in China has risen substantially over the past decade. For instance, according to WHO, in 2020, China had about 126.80 million diabetic patients, and this number is expected to reach 138.42 million by the end of 2026. China's urbanization and growing living standards, leading to reduced physical activity and unhealthy diets, are the significant factors behind the high rate of diabetes. In 2020, China accounted for 9.8% of Type 1 diabetes patients of the total diabetes population.
The increasing incidence of obesity population globally is expected to drive the global dependent insulinotropic receptor market growth.
Obesity is a major factor leading to diabetes. According to the WHO, in 2016, over 1.9 billion adults were overweight, of which around 650 million people were obese. Like obesity and overweight, risk factors are leading to an increase in the incidence of diabetes. Therefore, risk factors such as smoking, overweight, obesity, and high cholesterol levels are expected to boost the prevalence of diabetes.
Increased glucose-dependent insulinotropic peptide levels have a few disadvantages that hamper the market growth.
In type 2 diabetes mellitus, some patients have increased glucose-dependent insulinotropic peptide levels, but it is not known whether this is a cause or consequence of the condition. In type 2 diabetes mellitus, the glucose-dependent insulinotropic peptide does not function as well as it should, making it less efficient at stimulating insulin release. This means patients have high blood sugar (hyperglycemia), worsening their existing type 2 diabetes mellitus.
With obesity, scientists believe that by eating too many fatty foods, there is an over-production of glucose-dependent insulinotropic peptides, which produce more fat tissue.
COVID-19 Impact Analysis
The COVID-19 pandemic has exerted a tremendous strain on the healthcare framework in some countries. Moreover, people with chronic conditions are more at risk if contracted by COVID-19. According to the Centers for Disease Control and Prevention, more than 30 million people in the US have diabetes. This chronic disease affects how the body turns food into energy and the body's natural insulin production. Over time, diabetes increases the risk of severe health complications, including heart disease, blindness, and nerve and kidney damage. Improvement in blood sugar control through insulin, a standard treatment, can reduce the risk of some of these long-term complications. However, diabetic patients' lives are at high risk compared to ordinary people.
Segment Analysis
The DA-1241 segment is expected to hold the largest share in this market segment.
Unlike other G protein-coupled receptor (GPR)119 agonists, DA-1241 has long-term beneficial glucose and lipid metabolism. Fasting blood glucose level decreased, and the insulinogenic index was improved after DA-1241 treatment. DA-1241 reduced gluconeogenic enzyme expression and blocked autophagic flow in HepG2 cells. These findings suggested that DA-1241 augmented glucose-dependent insulin release via improvement in GLP-1 secretion and reduced hepatic gluconeogenesis, which might be associated with autophagic blockage, leading to improved glycaemic control.
The type 2 diabetes segment is expected to hold the largest share in this market segment.
Type II diabetes accounts for approximately 90-95% of diabetes cases, killing about 193,000 US residents each year. Type II diabetes is the seventh leading cause of all deaths. Type II diabetes currently affects 6% of the adult population in Western societies, with worldwide frequency expected to grow by 6% per annum. Although certain inheritable traits may predispose particular individuals to develop Type II diabetes, the driving force behind the current increase in the incidence of the disease is the increased sedentary lifestyle, diet, and obesity now prevalent in developed countries. About 80% of people with diabetes with Type II diabetes are significantly overweight. As noted above, many young people are developing the disease. Type II diabetes is now internationally recognized as one of the significant threats to human health in the 21stcentury.
Geographical Analysis
North America region holds the largest market share of the global dependent insulinotropic receptor market.
In 2020, the United States accounted for a majority of the revenue share (about 96%) in the market, mainly due to the increasing diabetic population in the country. According to a recent survey, about 9.4% of the total US population is diabetic, and about 1.75 million Americans are diagnosed with diabetes every year. Type 2 diabetes is increasingly prevalent but also largely preventable. According to the Centers for Disease Control and Prevention (CDC)Trusted Source, type 2 diabetes accounts for about 90 to 95 percent of all diagnosed cases of diabetes in adults. The growing research and developments, rising investments are the major factors driving the market. For instance,
|
Product |
Indication |
Phase |
|
MBX-2982 (GPR 119 agonist) |
Diabetic Hypoglycemia |
Phase 2 |
Source: DataM Intelligence Analysis (2020)
Competitive Landscape
The global dependent insulinotropic receptor market is moderately competitive with multinational companies. Some of the key players which are contributing to the growth of the market include Amgen Inc, Arena Pharmaceuticals Inc, CymaBay Therapeutics Inc, Dong-A Socio Holdings Co Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hyundai Pharmaceutical Co Ltd, Kowa Co Ltd, Merck and Co Inc, Novartis AG, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Co Ltd, Yuhan Corp. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the market's growth globally.
Dependent Insulinotropic Receptor Market Key Companies to Watch
Amgen Inc
Company Overview: Amgen (Applied Molecular Genetics Inc.) was established in Thousand Oaks, California, on April 8, 1980, is one of the world's leading biotechnology companies. It is a values-based company deeply rooted in science and innovation to transform new ideas and discoveries into medicines for serious illnesses. Amgen's subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, significantly improving identifying and validating human disease targets.
Product Portfolio: The Company's portfolio comprises six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.
Why Purchase the Report?
- Visualize the composition of the dependent insulinotropic receptor market segmentation by product type, application and region, highlighting the key commercial assets and players.
- Identify commercial opportunities in the dependent insulinotropic receptor market by analyzing trends and co-development deals.
- Excel data sheet with thousands of dependent insulinotropic receptor market points - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global dependent insulinotropic receptor market report would provide access to an approx. 40+ market data table, 45+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
